522 related articles for article (PubMed ID: 15659504)
1. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
Le Cesne A; Blay JY; Judson I; Van Oosterom A; Verweij J; Radford J; Lorigan P; Rodenhuis S; Ray-Coquard I; Bonvalot S; Collin F; Jimeno J; Di Paola E; Van Glabbeke M; Nielsen OS
J Clin Oncol; 2005 Jan; 23(3):576-84. PubMed ID: 15659504
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of ET-743: the French experience.
Brain EG
Anticancer Drugs; 2002 May; 13 Suppl 1():S11-4. PubMed ID: 12173489
[TBL] [Abstract][Full Text] [Related]
3. ET-743: the US experience in sarcomas of soft tissues.
Demetri GD
Anticancer Drugs; 2002 May; 13 Suppl 1():S7-9. PubMed ID: 12173492
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.
Yovine A; Riofrio M; Blay JY; Brain E; Alexandre J; Kahatt C; Taamma A; Jimeno J; Martin C; Salhi Y; Cvitkovic E; Misset JL
J Clin Oncol; 2004 Mar; 22(5):890-9. PubMed ID: 14990645
[TBL] [Abstract][Full Text] [Related]
5. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Garcia-Carbonero R; Supko JG; Manola J; Seiden MV; Harmon D; Ryan DP; Quigley MT; Merriam P; Canniff J; Goss G; Matulonis U; Maki RG; Lopez T; Puchalski TA; Sancho MA; Gomez J; Guzman C; Jimeno J; Demetri GD
J Clin Oncol; 2004 Apr; 22(8):1480-90. PubMed ID: 15084621
[TBL] [Abstract][Full Text] [Related]
6. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Garcia-Carbonero R; Supko JG; Maki RG; Manola J; Ryan DP; Harmon D; Puchalski TA; Goss G; Seiden MV; Waxman A; Quigley MT; Lopez T; Sancho MA; Jimeno J; Guzman C; Demetri GD
J Clin Oncol; 2005 Aug; 23(24):5484-92. PubMed ID: 16110008
[TBL] [Abstract][Full Text] [Related]
7. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
8. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
Delaloge S; Yovine A; Taamma A; Riofrio M; Brain E; Raymond E; Cottu P; Goldwasser F; Jimeno J; Misset JL; Marty M; Cvitkovic E
J Clin Oncol; 2001 Mar; 19(5):1248-55. PubMed ID: 11230465
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Le Cesne A; Reichardt P
Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
Laverdiere C; Kolb EA; Supko JG; Gorlick R; Meyers PA; Maki RG; Wexler L; Demetri GD; Healey JH; Huvos AG; Goorin AM; Bagatell R; Ruiz-Casado A; Guzman C; Jimeno J; Harmon D
Cancer; 2003 Aug; 98(4):832-40. PubMed ID: 12910529
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'รณ E; Colombo N
J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
Taamma A; Misset JL; Riofrio M; Guzman C; Brain E; Lopez Lazaro L; Rosing H; Jimeno JM; Cvitkovic E
J Clin Oncol; 2001 Mar; 19(5):1256-65. PubMed ID: 11230466
[TBL] [Abstract][Full Text] [Related]
15. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
Roylance R; Seddon B; McTiernan A; Sykes K; Daniels S; Whelan J
Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):572-6. PubMed ID: 17624747
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
Puchalski TA; Ryan DP; Garcia-Carbonero R; Demetri GD; Butkiewicz L; Harmon D; Seiden MV; Maki RG; Lopez-Lazaro L; Jimeno J; Guzman C; Supko JG
Cancer Chemother Pharmacol; 2002 Oct; 50(4):309-19. PubMed ID: 12357306
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
[TBL] [Abstract][Full Text] [Related]
18. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
19. RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma.
Therasse P; Le Cesne A; Van Glabbeke M; Verweij J; Judson I;
Eur J Cancer; 2005 Jul; 41(10):1426-30. PubMed ID: 15919202
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
Simpson EL; Rafia R; Stevenson MD; Papaioannou D
Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
